PillRx only · Injection, Powder, Lyophilized, For Solution · Intramuscular
Bleomycin
Bleomycin Sulfate
2 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US6 NDCs
2 active makers
2 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
US acquisition costNADAC · per unit
Average across 3 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
$26.448
Latest avg · Apr 22, 2026
+10%
Since Dec 17, 2025
2
Active US suppliers
100%
Top-2 supplier share*
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
178
Rx · 2026 Q1
255
Units dispensed
-46%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it2 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Hospira, Inc. | unknown | 4 | SUPPLYING |
| Hikma Pharmaceuticals USA Inc. | unknown | 2 | SUPPLYING |
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- Dec 21, 2023RECALLRecall (Class I): Bleomycin for Injection, USP, 15 units per vial, 1 single dose glass fliptop vial, Rx Only, Distributed by: Hospira, In…
Presence of particulate matter: glass — Recalling firm: PFIZER — Nationwide in the USA, Netherlands and Libya
- Aug 5, 2021RECALLRecall (Class III): Bleomycin for Injection, USP, packaged in 15 units per single dose vial, Rx only, Manufactured by Thymoorgan Pharmazie …
Labeling: Not elsewhere classified: Mislabeling — Recalling firm: Hikma Pharmaceuticals USA Inc. — USA nationwide